Appointment of new Chief Financial Officer
Accrol, the UK's leading independent tissue converter, is pleased to announce that Chris Welsh has today joined the Board as Chief Financial Officer ("CFO").
As detailed in the HY23 Results announcement, Chris succeeds Richard Newman, who has now resigned as CFO and stepped down from the Board but, to ensure a smooth transition, has agreed to remain with the Company until the FY23 audit process is completed and the Final Results are released.
Chris joined the business in October 2022, as part of the Board's succession planning. Before his move to Accrol, Chris held several senior finance roles at the multinational chemical manufacturing group, Ineos, most latterly as Head of Financial Reporting at the Enterprises Division.
Chris is a Chartered Accountant, who qualified with PwC in 2015.
Gareth Jenkins, Chief Executive Officer, said:
"We are delighted to welcome Chris to the Board. Since joining Accrol last year, he has been operating at the highest standard, demonstrating the commitment, energy and acumen which will help deliver our strategic objectives.
"I would also like to take this opportunity to thank Richard for his significant contribution to the Group. On appointment, he was tasked with transforming the finance function of the business, which he has achieved. Richard hands over to Chris a much strengthened finance team and infrastructure, capable of serving a much larger business."
Further information relating to Christopher Welsh
In accordance with Schedule 2(g) of the AIM rules, Christopher ("Chris") James Welsh (aged 33) holds or has held in the past five years the following directorships:
Accrol UK Limited
LTC Parent Ltd
John Dale Holdings Limited
Leicester Tissue Company Limited
Art Tissue Ltd
Accrol Papers Limited
Accrol Holdings Limited
John Dale Limited
Chris holds no shares in the Company.
There is no further information on Chris required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.